Celentyx Enters Into Agreement With Meiji Seika Kaisha, Ltd. To Discover New Development Paths For Meiji Drug Candidates Using Celentyx's Novel Clinical Indication Profiling(TM)
8/24/2009 11:54:55 AM
BIRMINGHAM, UK August 24, 2009 – Celentyx Ltd announced today that it has entered into a
drug reprofiling agreement with Meiji Seika Kaisha, Ltd to seek alternative development paths for
Meiji drug candidates using an application of the Immuno-Profiling platform™ called Novel
Clinical Indication Profiling™ (NCIP™). These drug candidates were previously discontinued or
de-prioritized for reasons other than safety.
Celentyx’s proprietary NCIP™ identifies new uses for 'safe' drugs to treat human immune system
diseases e.g. inflammation, haematological cancers (leukaemias and lymphomas), allergy,
autoimmune disease and graft rejection. Celentyx research is at the forefront of the discovery and
the elucidation of the role of novel targets in human immune system cells, many of these targets
having formally been associated solely with the CNS. This expertise offers pharmaceutical
partners a novel approach to bolster their pipelines with high-quality drug candidates that
originated from their own R&D efforts.
Professor Nicholas Barnes, CEO of Celentyx Ltd, said, "We are particularly pleased to add Meiji
as a partner since they have a number of candidate drugs impacting a target that we have identified
on key cell subsets within the human immune system. Celentyx’s NCIP™ provides an efficient
evaluation of a drug’s ability to signal responses in human immune cells with exceptionally high
resolution to determine the therapeutic potential of small molecules and biologicals. Our goal is to
provide partners with substantial value and revive development paths for drugs that retain potential
for immune system disorders."
About Celentyx Ltd
Celentyx Ltd is a human immune system focused R&D and service company. Celentyx’s unique
Immuno-Profiling™ platform allows identification of novel targets with therapeutic potential and
rapid analysis of drug action on human immune cells. Drawing on the World-leading expertise of
Celentyx personnel, which along with our close association with the MRC Centre for Immune
Regulation, enables the human immune system to be investigated at the highest levels of
Celentyx's Immuno-Profiling™ services also enable partners to elucidate the mechanism of action
of an immunomodulatory drug – at both the cellular and molecular level, facilitate lead candidate
prioritisation or identify potentially negative impact of a drug on the human immune system prior
to first administration to man.
About Meiji Seika Kaisha Ltd.
Meiji Seika Kaisha Ltd. is located in Tokyo, Japan and is operating its business in the fields of
confectionaries and pharmaceuticals. In the pharmaceutical division, Meiji Seika is dedicated to
the discovery, development and commercialization of a wide variety of pharmaceutical products
throughout Japan and some countries outside of Japan, as well. The main areas of its interest are
infectious disease and central nervous system disorders. For more information on Meiji Seika,
please visit the company’s website at www.meiji.co.jp.
comments powered by